Difference between revisions of "Team:UiOslo Norway"

Line 11: Line 11:
 
   width: 60%;
 
   width: 60%;
 
   margin-top: 10px;
 
   margin-top: 10px;
 +
  }
 +
 +
  .sponsors {
 +
  text-align: center;
 +
  }
 +
 +
  .sponsors > a {
 +
  width: 300px;
 +
  display: inline-block;
 +
  vertical-align: top;
 +
  margin-top: 30px;
 +
  }
 +
 +
  .sponsor::after {
 +
  content: "";
 +
  width: 100%;
 +
  display: inline-block;
 +
  }
 +
 +
  .logo {
 +
  height: 50px;
 +
  width: auto;
 
   }
 
   }
  
Line 31: Line 53:
 
<p style="text-align:justify;"><a href="https://2018.igem.org/Team:UiOslo_Norway/Attributions#inspiration">Based on previous projects</a>, UiOslo Norway aims to develop a fast detection kit for <em>C. albicans</em> infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guide RNAs, the dCas9 complexes bind adjacently on <em>C. albicans</em> specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of <em>C. albicans</em> DNA.
 
<p style="text-align:justify;"><a href="https://2018.igem.org/Team:UiOslo_Norway/Attributions#inspiration">Based on previous projects</a>, UiOslo Norway aims to develop a fast detection kit for <em>C. albicans</em> infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guide RNAs, the dCas9 complexes bind adjacently on <em>C. albicans</em> specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of <em>C. albicans</em> DNA.
 
</p>
 
</p>
 +
 +
<div class="sponsors">
 +
 +
<a href="https://www.uio.no/english/">
 +
  <img class="logo" src="https://static.igem.org/mediawiki/2018/3/32/T--UiOslo_Norway--UiO.png" target="_blank" alt="University of Oslo">
 +
</a>
 +
 +
<a href="https://eu.idtdna.com/pages">
 +
  <img class="logo" src="https://static.igem.org/mediawiki/2018/a/ae/T--UiOslo_Norway--IDT.png" target="_blank" alt="Integrated DNA Technologies">
 +
</a>
 +
 +
<a href="https://twistbioscience.com/">
 +
  <img class="logo" src="https://static.igem.org/mediawiki/2018/e/ea/T--UiOslo_Norway--Twist.png" target="_blank" alt="Twist Biosciences">
 +
</a>
 +
 +
 +
<a href="https://digitallifenorway.org/gb/">
 +
  <img class="logo" src="https://static.igem.org/mediawiki/2018/2/2a/T--UiOslo_Norway--CDL.png" target="_blank" alt="Centre for Digital Life Norway">
 +
</a>
 +
 +
<a href="https://www.biokjemisk.no/">
 +
  <img class="logo" src="https://static.igem.org/mediawiki/2018/e/e2/T--UiOslo_Norway--NBS.png" target="_blank" alt="Norwegian Biochemical Society">
 +
</a>
 +
 +
<a href="https://nordicbiosite.com/">
 +
  <img class="logo" src="https://static.igem.org/mediawiki/2018/b/b0/T--UiOslo_Norway--biosite.png" target="_blank" alt="Nordic BioSite">
 +
</a>
 +
 +
 +
<a href="https://sharelab.no">
 +
  <img class="logo" style="background-color: #1f374a; "src="https://static.igem.org/mediawiki/2018/8/87/T--UiOslo_Norway--sharelab.png" target="_blank" alt="Sharelab">
 +
</a>
 +
</div>
 +
 +
 +
 +
 
</div>
 
</div>
  
Line 38: Line 97:
 
</body>
 
</body>
 
</html>
 
</html>
−
{{:Team:UiOslo_Norway/Footer}}
 

Revision as of 21:43, 16 October 2018

Team members Collaboration
Description Design Results Demonstrate
Experiments Notebook Interlab
Parts Overview Basic Parts
Human Practices Integrated Human Practices Education & Engagement
Attributions Sponsors
Judging Form
Medal Criteria
Safety

Fast detection of vulvovaginal Candida albicans
infections using CRISPR/dCas9

Concept graphic

UiOslo Norway

During their lifetime 75 % of women will experience a Candida albicans (C. albicans) infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by C. albicans or not. In addition, women may purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult.

Based on previous projects, UiOslo Norway aims to develop a fast detection kit for C. albicans infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guide RNAs, the dCas9 complexes bind adjacently on C. albicans specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of C. albicans DNA.